Introduction
Cryptosporidium parvum is an important apicomplexan protozoan pathogen that significantly contributes to diarrheal disease in both humans and animals (Downey et al. 2008; Fayer 2004; Graczyk et al. 1997) . Throughout the world in immunocompetent hosts, Cryptosporidium infections are generally restricted to the intestinal epithelium, causing acute and self-limiting gastroenteritis. However, for HIV/AIDS patients and other immunocompromised individuals (organs transplant patients), such infection can result in life-threatening diarrheal disease (Ventura et al. 1997) . Recently, only nitazoxanide, a nitrothiazole benzamide, was approved by the Food and Drug Administration (FDA) for the treatment of cryptosporidiosis in immunocompetent adults and children over 1 year old (Anderson and Curann 2007) . However, this drug is not fully successful for all cases of cryptosporidiosis. Another drug, paromomycin, is well-known as a compound to treat C. parvum infections in animals and cell cultured models. Because Cryptosporidium currently and continuously causes over half of the reported waterborne disease outbreaks associated with exposure in chlorinated public swimming pool water (Dziuban et al. 2006; Ijaz et al. 2000; Sunderland et al. 2007) , research on new compounds to treat this disease is in progress.
The benzimidazole nucleus is present in numerous antiparasitic, fungicidal anthelmintic, and antiinflammatory drugs Bennamane et al. 2009; Kazimierczuk et al. 2002) . Albendazole, mebendazole, and benzimidazole carbamates affect the cycloskeleton and interact with tubulin of Giardia and other parasitic protozoa (Reynoldson et al. 1992) . The various benzimidazole derivatives were investigated as potential antiprotozoan drugs, mainly against Giardia, Entamoeba, or Trichomonas species (e.g., Perez-Villaneuva et al. 2010; Hernández-Luis et al. 2010) . Therefore, we decided to provide pilot screening tests using the benzimidazole derivatives of our laboratory resources against C. parvum. Of all tested compounds, the most promising appeared to be derivatives of 2-thiobenzimidazole-carrying additive substituents on the heterocyclic ring as well on the S-alkyl-benzyl chains. The major objective of the present study was the search for novel "leading structure" of heterocyclic compounds that would show promise as anticryptosporidial agents.
Materials and methods
Compounds Paromomycin was purchased from MP Biomedicals (Solon, OH, USA) and was diluted in water just prior to use. The tested compounds were obtained according the methods previously described Pinna 2004, 2005; Narkhede et al. 2007; Pagano et al. 2004 ).
C. parvum oocysts C. parvum (Iowa isolate) oocysts were obtained through experimental infection of a female Holstein calf. The protocol for animal infection was approved by the animal care and use committee of the Cornell University, College of Veterinary Medicine, Ithaca, New York, USA. The oocysts were extracted from the feces using continuous-flow centrifugation, purified by cesium chloride gradient centrifugation, and stored at 4°C in phosphate-buffered saline (PBS) (pH 7.4) Fig. 1 .
Compound activity in cell culture HCT-8 cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI 1640 medium supplemented with 10% Opti-MEM (GIBCO-BRL, Grand Island, NY, USA), 2% fetal bovine serum, and 2 mM L-glutamine. To determine in vitro drug efficacy, a quantitative alkaline phosphatase immunoassay was used to measure parasite growth inhibition in cell culture as described previously (Gargala et al. 1999; Woods et al. 1995) . Briefly, 96-well, flat-bottom microtiter plates were seeded with 5×10 4 HCT-8 cells 24 h prior to infection. For infection, the maintenance medium was removed and 5×10 3 oocysts were added to wells in 100 μl of RPMI 1640 supplemented with 10% fetal bovine serum and 0.05% bile salts. After incubation at 37°C for 90 min to induce excystation and to allow cell invasion, cells were washed once with warm PBS to remove unexcysted oocysts and free sporozoites. Negative control wells to measure background absorbance received 5×10 3 nonviable oocysts subjected to 5 cycles of freezing in liquid nitrogen and thawing in a 37°C water bath. Drugs were diluted to appropriate concentrations (Fig. 2 ) and added to cells in 150 μl of parasite growth medium. Paromomycin was used for comparison. Each drug concentration was tested in triplicates in two independent experiments. Plates were first incubated for 48 h at 37°C in 5% CO 2 -95% humidified air incubator, and then fixed in 8% formalin for 2 h at 22°C. After fixation, plates were washed three times with PBS and then blocked for 1 h with 300 μl of a blocking solution consisting of 5% bovine serum albumin (BSA) and 0.002% Tween 20 in PBS. Rat anti-Cryptosporidium polyclonal sera were diluted 1:500 in a solution of 1% BSA-0.002% Tween 20 in PBS, and 50 μl was added to each well. After 30-min incubation at 22°C, the wells were washed three times with PBS, and 50 μl of a horseradish peroxidaseconjugated goat anti-rat secondary antibody diluted 1:2,000 in 1% BSA-0.002% Tween 20-PBS was added to each well. After 20 min, plates were washed three times with PBS, and 100 μl of a 3,3′,5,5′-tetramethylbenzidine The background absorbance reading taken from wells receiving freeze-thawed oocysts was subtracted from all absorbance readings from drug-treated and control wells, and the percentage of growth inhibition was calculated as 1 À mean A 450 of infected wells with drug=mean A 450 of ð ½ infected wells without drugÞ Â 100%. The mean values obtained from triplicate readings in two independent experiments were assessed for their significance by the nonparametric test, i.e., median t test. Significance was considered at P<0.05.
Results and discussion
The effect of paromomycin and 11 different benzimidazole derivatives on parasite growth were investigated in cell culture by exposure of C. parvum-infected cells to the antimicrobial compounds for 48 h. Paromomycin was used as a reference compound.
The present study demonstrated that the 9 of 11 tested benzimidazole derivatives reduced the number of developmental stages of C. parvum in vitro. In particular, compounds 5, 7, and 8 were comparable to paromomycin in inhibiting pathogen growth. Paromomycin is commonly used to treat Cryptosporidium-infected animals and immunocompetent humans. However, this drug is expensive and produces serious side effects, thus cannot be used for immunocompromised individuals with weakened liver functions. Thus, variously substituted benzimidazoles on the benzene nucleus carrying additional nitrobenzylthio substituents at position 2 could be further tested for use in the treatment of cryptosporidiosis in both immunocompetent and immunocompromised individuals.
The mechanisms of Cryptosporidium growth inhibition by the compounds tested in the present study are not clear. However, it is most likely related to the absorption of the drug through Cryptosporidium trophozoite membranes. It is noteworthy that compounds 1 and 4 being "core structures" for other derivatives were essentially nonactive in the test experiments with their inhibitory concentration values significantly elevated in comparison to paromomycin (median t test; P<0.05) (Fig. 2) . However, introduction of the halogen atoms or carboxyl group onto benzene part of benzimidazole enhances the efficacy of investigated compounds against Crytosporidium. Also, the presence of nitro group or chlorine atoms in the benzylthio part of molecule positively affected antiparasitic activity of the compounds. For this study, we selected only the compounds which have some structural elements typical for nitoxazide (nitrogroup in the side ring) or halogen atoms (chlorophenyltriazole derivatives) (Sharling et al. 2010) . It seems also that in the alkylthio residue, the additional functional group is necessary as observed based on anti-C. parvum activity obtained by compounds 1, 2, and 3. Further studies are necessary to reveal and substantiate the function of the benzimidazole derivatives as prospective anticrysporidial drug candidates.
Testing of the efficacy of the benzimidazole derivative compounds in vitro against developmental stages of Cryptosporidium is the first step in drug testing. Based on the ID 50 values obtained in the present study for these 11 compounds, we conclude that all produced an elevated level of effectiveness that warrants the next phase of investigation to focus on toxicity and animal infection testing. However, our attention will be particularly focused on the three compounds, i.e., 5, 7, and 8 since their efficacy was shown to be superior to paromomycin.
The ideal drug for treatment of cryptosporidiosis or any other intestinal protozoa infection in immunocompetent and immunocompromised patients should be easy absorbable by the intestinal epithelium (which is site of Cryptosporidium infection) and should be effective at low dosage without producing side effects (Downey et al. 2009 ). However, if a drug does not produce side effects, the dose and frequency of treatment are irrelevant. The compounds tested in the present study are not watersoluble but soluble in lipids which assures their: (1) emulsification in the intestinal lumen; (2) easy absorption by the intestinal epithelium; and (3) a direct inhibitory effect on Cryptosporidium developmental stages covering intestinal epithelium microvilli.
Because there are not enough directly relevant studies and results for treatment of C. parvum infections and this genus includes another human infectious species, Cryptosporidium hominis (Xiao et al. 2001 ), we will test the compounds in animal models. Anti-diarrheal medicine may retard diarrhea, but a health care provider should be consulted before such medicine is administered (Downey et al. 2008) . Nitazoxanide is FDA-approved for treatment of diarrhea caused by Cryptosporidium in humans with healthy immune systems and is available by prescription. However, the effectiveness of nitazoxanide in immunosuppressed individuals is unclear.
HIV positive individuals who suspect they have cryptosporidiosis should contact their health care provider. For those persons with AIDS, anti-retroviral therapy that improves the immune status will also decrease or eliminate symptoms of cryptosporidiosis. However, even if symptoms disappear, cryptosporidiosis is often not curable and the symptoms may return if the immune status worsens.
